InsidersTradesSigma
Follow the KYNTRA BIO, INC. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.5bn. The latest transaction was filed on 9 June 2026 (Retenue fiscale). Among the most active insiders: DeLucia David. All data is free.
Analysts rate KYNTRA BIO, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
KYNTRA BIO, INC. is a biotechnology company focused on developing innovative treatments for chronic diseases. It is listed on the NASDAQ under the ticker KYNTRA.